A recent retrospective review of the literature and clinical trials, published in the American Journal of Roentgenology (AJR), reports percutaneous (through the skin) microwave ablation (MWA) is a promising treatment strategy for patients with early stage cT1 kidney tumours.
The review suggests that more research into the selection of patients for this treatment, and the risks associated with microwave ablation is needed. According to the researchers, risks from microwave ablation include major bleeding and genitourinary-tract complications. The review was carried out be researchers from the Mayo Clinic in Rochester, Minnesota, USA.
Read a summary of the review in Cancer Therapy Advisor here